Page 77 - 《中国药房》2023年22期
P. 77

[ 6 ]  肖若薇,李薇,孙文韬,等. 使用静脉铁剂的住院患者贫                       al. Switching iron sucrose to ferric carboxymaltose asso-
              血治疗现状真实世界研究[J]. 临床药物治疗杂志,2022,                      ciates to better control of iron status in hemodialysis pa‐
              20(6):67-71.                                        tients[J]. BMC Nephrol,2018,19(1):242.
              XIAO R W,LI W,SUN W T,et al. Current status of ane‐  [15]  CALLEJA J L,DELGADO S,DEL VAL A,et al. Ferric
              mia treatment in inpatients treated with intravenous iron:a   carboxymaltose  reduces  transfusions  and  hospital  stay  in
              real-world study[J]. Clin Med J,2022,20(6):67-71.   patients with colon cancer and anemia[J]. Int J Colorectal
          [ 7 ]  ClinicalTrials.gov. To assess the impact of ferric carboxy‐  Dis,2016,31(3):543-551.
              maltose  compared  with  iron  sucrose  in  Chinese  subjects   [16]  FROESSLER B,PALM P,WEBER I,et al. Reply:the im‐
              on  correcting  iron  deficiency  anemia[EB/OL].  [2023-05-  portant  role  for  intravenous  iron  in  perioperative  patient
              14]. https://www.clinicaltrials.gov/ct2/show/NCT03591406?  blood management in major abdominal surgery:a rando-
              Term=NCT03591406&draw=2&rank=1.                     mized  controlled  trial[J]. Ann  Surg,2018,267(3):e49-
          [ 8 ]  金洁,冉志华. 一项在中国人群中评估羧基麦芽糖铁与                        e50.
              蔗糖铁相比治疗缺铁性贫血的开放性、随机对照多中心                       [17]  KHALAFALLAH A A,YAN C,AL-BADRI R,et al. In‐
              3期研究[C]//2022中华医学会第十七次全国血液学学术                       travenous  ferric  carboxymaltose  versus  standard  care  in
              会议,上海:中华医学会,2022.                                   the management of postoperative anaemia:a prospective,
              JIN J,RAN Z H. An open,randomised controlled multi‐  open-label,randomised controlled trial[J]. Lancet Haema‐
              centre phase 3 trial evaluating ferric carboxymaltose com‐  tol,2016,3(9):e415-e425.
              pared  with  iron  sucrose  for  the  treatment  of  iron  defi‐  [18]  SPAHN D R,SCHOENRATH F,SPAHN G H,et al. Ef‐
              ciency  anaemia  in  the  Chinese  population[C]//The  17th   fect of ultra-short-term treatment of patients with iron defi‐
              National Hematology Symposium of the Chinese Medical   ciency or anaemia undergoing cardiac surgery:a prospec‐
              Association,2022,Shanghai:Chinese  Medical  Associa‐  tive randomised trial[J]. Lancet,2019,393(10187):2201-
              tion,2022.                                          2212.
          [ 9 ]  LATIMER  N  R.  Survival  analysis  for  economic  evalu-  [19]  KIM S K,SEO W Y,KIM H J,et al. Postoperative intra‐
              ations alongside clinical trials:extrapolation with patient-  venous ferric carboxymaltose reduces transfusion amounts
              level  data[M].  London:National  Institute  for  Health  and   after orthopedic hip surgery[J]. Clin Orthop Surg,2018,10
              Care Excellence(NICE),2013:1.                      (1):20-25.
          [10]  CALVET  X,GENÉ  E,ÀNGELRUÍZ  M,et  al.  Cost-  [20]  STRAUSS W E,AUERBACH  M. Health-related quality
              minimization analysis favours intravenous ferric carboxy‐  of life in patients with iron deficiency anemia:impact of
              maltose  over  ferric  sucrose  or  oral  iron  as  preoperative   treatment with intravenous iron[J]. Patient Relat Outcome
              treatment in patients with colon cancer and iron deficiency   Meas,2018,9:285-298.
              anaemia[J]. Technol Health Care,2016,24(1):111-120.  [21]  YANG Z H,BUSSCHBACH J,LIU G,et al. EQ-5D-5L
          [11]  BISBE E,GARCÍA-ERCE J A,DÍEZ-LOBO A I,et al. A    norms  for  the  urban  Chinese  population  in  China[J].
              multicentre comparative study on the efficacy of intrave‐  Health Qual Life Outcomes,2018,16(1):210.
              nous ferric carboxymaltose and iron sucrose for correcting   [22]  WU D,ZHANG Y,BOEGELUND M,et al. PR4 health
              preoperative  anaemia  in  patients  undergoing  major  elec‐  utility assessment of different options for treatment of iron
              tive surgery[J]. Br J Anaesth,2011,107(3):477-478.  deficiency  anemia:results  from  time-trade-off  study  in
          [12]  ROGNONI  C,ORTALDA  V,BIASI  C,et  al.  Economic   China[J]. Value Health,2021,24:S197.
              evaluation  of  ferric  carboxymaltose  for  the  management   [23]  官海静,周宗科,刘腾,等. 不同蔗糖铁注射液用于骨科
              of  hemodialysis  patients  with  iron  deficiency  anemia  in   围手术期贫血的效果及费用比较[J]. 临床药物治疗杂
              Italy[J]. Adv Ther,2019,36(11):3253-3264.           志,2022,20(4):32-36.
          [13]  LACQUANITI A,PASQUALETTI P,TOCCO T C D,et         GUAN H J,ZHOU Z K,LIU T,et al. Effectiveness and
              al. Ferric carboxymaltose versus ferric gluconate in hemo‐  medical  expenditure  of  iron  sucrose  in  the  treatment  of
              dialysis  patients:reduction  of  erythropoietin  dose  in  4   iron deficiency anemia during perioperative period of or‐
              years  of  follow-up[J].  Kidney  Res  Clin  Pract,2020,39  thopedic surgery[J]. Clin Med J,2022,20(4):32-36.
              (3):334-343.                                                  (收稿日期:2023-01-11  修回日期:2023-10-26)
          [14]  HOFMAN J M G,EISENGA M F,DIEPENBROEK A,et                                         (编辑:孙 冰)











          中国药房  2023年第34卷第22期                                              China Pharmacy  2023 Vol. 34  No. 22    · 2755 ·
   72   73   74   75   76   77   78   79   80   81   82